Prescribing, Policies and Pathways
Medicine / Guideline | Indication | RAG rating | Document type | Place |
---|---|---|---|---|
Aazathioprine / mercaptopurine | Multisystem autoimmune disease | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Aazathioprine / mercaptopurine | Multisystem autoimmune disease | Amber protocol | Shared care protocol | West Essex |
Abaloparatide | Osteoporosis after menopause | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Abatacept | Psoriatic arthritis | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Abatacept | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Abrocitinib | Atopic dermatitis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Acamprosate | Alcohol misuse | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Acamprosate | Alcohol misuse | n/a | Patient information | West Essex |
Acamprosate | Alcohol misuse | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Acamprosate | Alcohol misuse | Amber initiation | Prescribing guideline | West Essex |
Acetylcholinesterase (AChE) inhibitor | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
Acetylcholinesterase (AChE) inhibitor | Alzheimer's disease dementia | Amber initiation | Prescribing support document | East and North Hertfordshire, South and West Hertfordshire |
Acitretin | Psoriasis, ichthyosis, Darier's disease | Red | Decision document | Hertfordshire and West Essex ICB |
Acne vulgaris | Acne vulgaris | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Actinic keratosis | Actinic keratosis | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Acute trial of rimegepant for treatment of migraine - patient questionnaire | Migraine - treating | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Adalimumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Adalimumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Adalimumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Adalimumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Adalimumab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Adalimumab | Rheumatoid arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Adalimumab | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Adalimumab | Uveitis - non-infectious (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Adult ONS & care homes - Position statement | Nutrition support - Malnutrition | n/a | Position statement | Hertfordshire and West Essex ICB |
Adult ONS & end of life - Position statement | Nutrition support - End of life | n/a | Position statement | Hertfordshire and West Essex ICB |
Adult ONS in primary care - Quick guide | Nutrition support - Malnutrition | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Adult ONS, dessert style - Position statement | Nutrition support - Malnutrition | Double Red | Position statement | Hertfordshire and West Essex ICB |
Aflibercept | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Aflibercept | Vascular endothelial growth factor A inhibitor (anti-VEGF), Wet Age-related Macular Degeneration, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), Choroidal neovascularisation (CNV) associated with pathological myopia | Red | Decision document | Hertfordshire and West Essex ICB |
Agomelatine | Major depressive episodes | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Alemtuzumab | Highly active relapsing remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Alendronic acid | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Alimemazine | All indications, execluding sedation in paediatrics prior to diagnostic scans | Red | n/a | Hertfordshire and West Essex ICB |
Alimemazine switch patient letter | Allergy | Double Red | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Alirocumab | Primary hypercholesterolaemia and mixed dyslipidaemia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Aliskiren | Hypertension | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Alitretinoin | Eczema - hand severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Allergic rhinitis pathway | Allergic rhinitis | Green | Prescribing pathway | Hertfordshire and West Essex ICB |
Allopurinol | Gout 1st line | Green | n/a | Hertfordshire and West Essex ICB |
Alteplase | Acute ischaemic stroke | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Amantadine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Ambrisentan | Pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Amifampridine | Lambert-Eaton myasthenic syndrome (NHSE) | Double Red | n/a | Hertfordshire and West Essex ICB |
Amikacin | Cystic fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Amiodarone Shared Care Protcol | Arrythmia | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Amitriptyline | Irritable bowel syndrome (IBS) 2nd line unlicensed | Green | n/a | Hertfordshire and West Essex ICB |
Anagrelide | Reduction of elevated platelet counts | Red | n/a | Hertfordshire and West Essex ICB |
Anal fissure | Anal fissure | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Anaphylaxis Auto Adrenaline Injector | Anaphylaxis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Anastrozole | Familial breast cancer | n/a | NICE technology appraisal | Hertfordshire and West Essex ICB |
Andexanet alfa | Reversal of anticoagulation | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Antibiotic toolkit TARGET | Antimicrobial stewardship | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Anticholinergic burden (ACB) | Structured medication review Eclipse Live | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Anticholinergic burden (ACB) | Structured medication review Hints and tips | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Antihistamine | Seasonal allergic rhinitis - OTC | n/a | Position statement | Hertfordshire and West Essex ICB |
Antipsychotic depot injections | Schizophrenia | Red | n/a | Hertfordshire and West Essex ICB |
Apixaban (generic 1st line) | Atrial fibrillation | Green | n/a | Hertfordshire and West Essex ICB |
Apixaban (generic 1st line) | Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent DVT and PE | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Apixaban (generic 1st line) | VTE prophylaxis following hip and knee surgery | Red | n/a | Hertfordshire and West Essex ICB |
Apomorphine | Parkinson's disease | Red | Decision document | Hertfordshire and West Essex ICB |
Apremilast | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Apremilast | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Aripiprazole | Moderate to severe manic episodes in adolescents with bipolar I disorder | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Armour thyroid | Hypothyroidism | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Asthma | Adults 18 years and over | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Asthma | Children 5 to 19 years | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Asthma | Step down guidance | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Asthma | MART | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Asthma | Inhaled corticosteroids (ICS) choices | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Atogepant | Migraine - prevention | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Atomoxetine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
Atomoxetine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Attention deficit hyperactivity disorder (ADHD) | FAQs | n/a | Primary Care prescribing resource | South and West Hertfordshire |
Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol | Amber protocol | Shared care protocol | West Essex |
Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol - children, young people and adults | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol children and young people (methylphenidate, lisdexamfetamine, dexamfetamine, atomoxetine or guanfacine) | Amber protocol | Shared care protocol | West Essex |
Avatrombopag | Primary chronic immune thrombocytopenia | Red | Decision document | Hertfordshire and West Essex ICB |
Avatrombopag | Thrombocytopenia in chronic liver disease | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Aveeno switch patient letter | Emollient | Double Red | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Axial Spondyloarthritis | Axial Spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Azithromycin | COPD | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Azithromycin in adults with COPD | Azithromycin in adults with COPD - prophylactic | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Aztreonam lysine | Cystic fibrosis chronic pseudomonas aeruginosa (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Baricitinib | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Baricitinib | Alopecia areata | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Baricitinib | Atopic dermatitis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Bath and shower preparations | Dry and pruritic skin conditions | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Behavioural and Psychological Symptoms of Dementia (BPSD) | Dementia | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Bempedoic acid | Primary hypercholesterolaemia or mixed dyslipidaemia | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Benralizumab | Severe eosinophilic asthma (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Bevacizumab | Vascular endothelial growth factor A inhibitor (anti-VEGF), Wet Age-related Macular Degeneration, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), Choroidal neovascularisation (CNV) associated with pathological myopia | Red | Decision document | Hertfordshire and West Essex ICB |
Bevacizumab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Bezlotoxumab | Clostridium difficile | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Bictegravir | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Bile salts malabsorption | Bile salts malabsorption | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Bimekizumab | Axial Spondyloarthritis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Bimekizumab | Psoriatic arthritis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Bimekizumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Biologic and Biosimilar Medicines | Where indicated | n/a | Patient information | Hertfordshire and West Essex ICB |
Biosimilar insulins (Admelog Semglee and Trurapi) | Diabetes | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Bisphosphonates | Osteoporosis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Blepharitis | Blepharitis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Blood glucose and ketone meters, test strips and lancets | Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Blood glucose meters, test strips and lancets | Type 2 diabetes | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Blood glucose test strips and lancets quantity calculator | Diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Bosentan | Digital ulcers and pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Botulinum neurotoxin type A | Sialorrhoea | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Botulinum toxin type A | Focal spasticity, Hemi-facial spasm, Blepharospasm, Cervical dystonia, Frey’s syndrome, Chronic anal fissure, Dysphagia, Hirschsprung’s disease, Overactive bladder,Masseteric hypertrophy and temporomandibular disorders | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Brodalumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Brolucizumab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Brolucizumab | Wet Age-related Macular Degeneration, Diabetic macular oedema | Red | Decision document | Hertfordshire and West Essex ICB |
Bronchiectasis | Bronchiectasis - acute exacerbation of (non-cystic fibrosis) | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Budesonide - rectal (Budenofalk) | Ulcerative colitis | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Budesonide (Jorveza) | Inducing remission of eosinophilic oesophagitis | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Budesonide targeted release (Kinpeygo) | Primary IgA nephrology | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Buprenorphine oral lyophilisate | Opioid drug dependence | Double Red | Decision document | Hertfordshire and West Essex ICB |
Calcium & vitamin D | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Canagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Candidiasis | Candidiasis - oral | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Candidiasis | Candidiasis - vaginal | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Cangrelor | Reduction of atherothrombotic events in PCI | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Cannabis-based medicinal preparations | Intractable nausea & vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy | Red | Position statement | Hertfordshire and West Essex ICB |
Carbamazepine | Epilepsy | Green | n/a | Hertfordshire and West Essex ICB |
Care home malnutrition management pathway | Nutrition support - Malnutrition | n/a | Clinical pathways | Hertfordshire and West Essex ICB |
Care Home Newsletter | n/a | Prescribing support document | Hertfordshire and West Essex ICB | |
Care homes - Fortifying food | Nutrition support - Malnutrition | n/a | Patient information | Hertfordshire and West Essex ICB |
Care homes - Medication pots poster | Medication Administration | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Care homes & ONS - Relatives and friends information | Nutrition Support - Malnutrition | n/a | Patient information | Hertfordshire and West Essex ICB |
Casirivimab plus imdevimab | Covid-19 | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Catheter formulary | Continence | n/a | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Catheter formulary | Continence | n/a | Prescribing guideline | West Essex |
Catheter Prescription Ordering Form | Continence | n/a | Primary Care prescribing resource | East and North Hertfordshire, South and West Hertfordshire |
Cefiderocol | Drug-resistant gram-negative bacterial infections severe (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ceftazidime with avibactam | Drug-resistant gram-negative bacterial infections severe (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Cellulitis and erysipelas | Cellulitis and erysipelas | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Cenobamate | Focal onset seizures | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Certoliziumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Certolizumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Certolizumab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Certolizumab | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Chlamydia trachomatis / urethritis | Chlamydia trachomatis / urethritis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Chlorambucil | Cancer indications | Red | n/a | Hertfordshire and West Essex ICB |
Chlormethine gel | Mycosis fungoides-type cutaneous T-cell lymphoma (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ciclosporin eye drops | Dry eye disease that has not improved despite treatment with artificial tears | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Cilostazol | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Cinacalcet | Secondary Hyperparathyroidism in Adults with End Stage Kidney Disease Requiring Renal Replacement Therapy | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Ciprofibrate | Hypercholesterolaemia | Double Red | n/a | Hertfordshire and West Essex ICB |
Cladribine | Relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Clomipramine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Clonazepam | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Clonidine | Attention deficit hyperactivity disorder (ADHD) | Red | Decision document | Hertfordshire and West Essex ICB |
Clostridioides difficile infection | Clostridioides difficile infection | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Clozapine | Schizophrenia | Red | n/a | Hertfordshire and West Essex ICB |
Co-beneldopa | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Co-careldopa | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Co-careldopa (Carbidopa/levodopa) intestinal gel | Parkinson's disease (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Co-careldopa Intestinal Gel (Duodopa) | Parkinson's Disease (NHSE tertiary centre only) | Red | n/a | Hertfordshire and West Essex ICB |
Co-danthramer | Constipation - restricted to constipation in terminally ill patients of all ages | Green | Decision document | Hertfordshire and West Essex ICB |
Co-proxamol | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Co-proxamol | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
Colchicine | Gout 2nd line | Green | n/a | Hertfordshire and West Essex ICB |
Cold sores | Cold sores | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Colesevelam | Bile acid sequestrants for prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Colesevelam 2nd line | Diarrhoea associated with bile acid malabsorption | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Colestyramine | Bile acid sequestrants for prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Colestyramine 1st line | Diarrhoea associated with bile acid malabsorption | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Colistimethate sodium (Colobreathe) | Cystic fibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Combodart ((tamsulosin/ dutasteride) | Benign prostatic hyperplasia | Double Red | n/a | Hertfordshire and West Essex ICB |
COPD | COPD - acute exacerbation of | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
COPD | COPD | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
COPD treatment guidelines | COPD | n/a | Decision document | Hertfordshire and West Essex ICB |
Cough | Cough - acute | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Crohn's disease | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Cystistat | Chronic inflammation or infection of the bladder | Double Red | Decision document | Hertfordshire and West Essex ICB |
Cytisine | Smoking cessation | Double Red | n/a | Hertfordshire and West Essex ICB |
Dalteparin | Anticoagulation | Red | n/a | Hertfordshire and West Essex ICB |
Dapagliflozin | Chronic Heart Failure | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Dapagliflozin | Diabetes type 1 | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dapagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Dapoxetine | Premature ejaculation | Double Red | Decision document | Hertfordshire and West Essex ICB |
Darbepoetin | Anaemia with chemotherapy (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Darbepoetin | Anaemia with chronic kidney disease | Red | Decision document | Hertfordshire and West Essex ICB |
Daridorexant | Long-term insomnia | Green | Prescribing support document | Hertfordshire and West Essex ICB |
Daridorexant | Insomnia | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Daridorexant | Long-term insomnia | Green | Patient information | Hertfordshire and West Essex ICB |
Darunavir | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Darvadstrocel | Complex perianal fistulas in Crohns disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dasatinib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Deferasirox | Blood transfusion related iron overload in patients with myelodysplastic syndrome | Double Red | Decision document | Hertfordshire and West Essex ICB |
Deferiprone | Blood transfusion related iron overload in patients with myelodysplastic syndrome | Double Red | Decision document | Hertfordshire and West Essex ICB |
DEKAs Plus multivitamin | Paediatric patients with Cystic Fibrosis following tertiary care guidance | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Denosumab | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Denosumab letter template | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Denosumab prescribing support document | Osteoporosis | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Denosumab Xgeva® | Prevention of skeletal-related events (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dental abscess | Dental abscess | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Dependence forming medicine | Pain - ECF FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Dermatophyte infection | Dermatophyte infection: skin | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Dermatophyte infection | Dermatophyte infection: nail | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Desferrioxamine | Blood transfusion related iron overload in patients with myelodysplastic syndrome | Double Red | Decision document | Hertfordshire and West Essex ICB |
Deucravacitinib | Psoriasis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dexamethasone intravitreal implant | Diabetic macular oedema | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dexamethasone intravitreal implant | Uveitis - non-infectious | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
Dexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Dexamfetamine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Dexcom ONE | Diabetes letter continuation (west Essex) | Amber initiation | Prescribing guideline | West Essex |
Dexcom ONE | Diabetes letter initiation (west Essex) | Amber initiation | Prescribing guideline | West Essex |
Dexcom ONE | Diabetes letter discontinuation (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Dexcom ONE | Diabetes letter initiation (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Dexcom ONE | Diabetes letter continuation (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Dexcom ONE | Diabetes letter self funder (Herts) | Amber initiation | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Dexcom ONE | Diabetes | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Dexcom ONE | Diabetes | Amber initiation | Patient information | Hertfordshire and West Essex ICB |
Dexcom ONE FAQcs (West Essex) | T1DM | Amber initiation | Patient information | West Essex |
Dexcom ONE FAQs (Herts) | T1DM | Amber initiation | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Diabetes type 1 | What to do when you are ill | n/a | Patient information | Hertfordshire and West Essex ICB |
Diabetes type 2 | What to do when you are ill | n/a | Patient information | Hertfordshire and West Essex ICB |
Diabetes type 2 | Diabetic ketoacidosis (DKA) | n/a | Patient information | Hertfordshire and West Essex ICB |
Diabetic foot infection | Diabetic foot infection | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Diarrhoea | Diarrhoea infectious | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Diarrhoea | Diarrhoea - Traveller’s | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Dibotermin alfa | Promotion of ectopic bone formation | Red | Decision document | Hertfordshire and West Essex ICB |
Diclofenac sodium 3% gel | Actinic keratosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Dicycloverine | Irritable bowel syndrome (IBS) | Double Red | n/a | Hertfordshire and West Essex ICB |
Dienogest | Endometriosis | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Diltiazem ointment 3rd line | Anal fissures | Green | n/a | Hertfordshire and West Essex ICB |
Dimethyl fumarate | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Dipeptidyl peptidase-4 inhibitors (Gliptins) | Diabetes type 2 | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Diverticulitis | Diverticulitis - acute | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
DOACs | Anticoagulation - Atrial fibrillation (AF) guidance | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
DOACs | Anticoagulation - interactions | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
DOACs | Anticoagulation - counselling checklist | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Docusate sodium | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Dolutegravir | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Domperidone | Nausea vomiting in children | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Donepezil | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
Dornase alfa | Cystic fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Dosulepin | Depression | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Dosulepin Patient Information Leaflet | Depression | n/a | Patient information | Hertfordshire and West Essex ICB |
Dosulepin stopping and switching guidance | Depression | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Doxazosin (prolonged release) | Hypertension, benign prostatic hyperplasia (BPH) | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Doxazosin Prolonged-Release Patient Information Leaflet | Hypertension, benign prostatic hyperplasia (BPH) | n/a | Patient information | Hertfordshire and West Essex ICB |
Doxylamine with Pyridoxine (Xonvea®) | Nausea and Vomiting in pregnancy | Double Red | n/a | Hertfordshire and West Essex ICB |
Dronedarone - Adults | Arrythmia | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Dual GIP with GLP-1 RA or GLP-1 RA with Insulin guidance document | Type 2 Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Dual GIP with GLP-1 RA or GLP-1RA comparison document | Type 2 Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Dupilumab | Eosinophilic oesophagitis | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dupilumab | chronic rhinosinusitis with nasal polyps | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dupilumab | Prurigo Nodularis | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Dupilumab | Atopic dermatitis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Eating & drinking at end of life | Nutrition support - End of life | n/a | Patient information | Hertfordshire and West Essex ICB |
Eating well - Homemade supplements | Nutrition support - Malnutrition | n/a | Patient information | Hertfordshire and West Essex ICB |
Eating well - Quick guide | Nutrition support - Malnutrition | n/a | Patient information | Hertfordshire and West Essex ICB |
Eating well for small appetites | Nutrition support - Malnutrition | n/a | Patient information | Hertfordshire and West Essex ICB |
Eating, drinking & ageing well | Healthy eating - Older adults | n/a | Patient information | Hertfordshire and West Essex ICB |
Eclipse Live | Advice and Guidance FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Eczema (bacterial infection) | Eczema (bacterial infection) | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Efavirenz | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Elbasvir | Hepatitis C (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Electronic Cigarettes and other novel nicotine containing products | Tobacco dependance | Red | Position statement | Hertfordshire and West Essex ICB |
Elleste Duet | Hormone replacement therapy (HRT) | Green | n/a | Hertfordshire and West Essex ICB |
Eltrombopag | Thrombocytopenia related to hepatitis C | Red | Decision document | Hertfordshire and West Essex ICB |
Eltrombopag | Aplastic anaemia | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Eltrombopag ITP | Chronic immune thrombocytopenia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Emollients | Dry and pruritic skin conditions | n/a | Patient information | Hertfordshire and West Essex ICB |
Empagliflozin | Chronic Heart Failure | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Empagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Emtricitabine | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
End of life | Anticipatory prescribing chart v4 | Green | Primary Care prescribing resource | East and North Hertfordshire, South and West Hertfordshire |
End of life | Anticipatory prescribing guidance v2 | n/a | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Enoxaparin | Anticoagulation | Red | n/a | Hertfordshire and West Essex ICB |
Entacapone | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Entecavir | Hepatitis B (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Epididymitis | Epididymitis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Epoetin | Anaemia with chronic kidney disease | Red | Decision document | Hertfordshire and West Essex ICB |
Epoietin | Anaemia with chemotherapy (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Eptinezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Eptinezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Erenumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Erenumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Erlotinib | All indications (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
Erythropoiesis stimulating agents | Anaemia with chronic kidney disease | Red | Decision document | Hertfordshire and West Essex ICB |
Esketamine | Depression - major | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Etanercept | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Etanercept | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Etanercept | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Etanercept | Rheumatoid arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Etanercept | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Ethosuximide | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Ethosuximide capsules | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Ethosuximide syrup | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Etoposide | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Etrasimod | Ulcerative Colitis - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Evolocumab | Primary hypercholesterolaemia and mixed dyslipidaemia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Evorel | Hormone replacement therapy (HRT) Patches are 2nd choice when tablets not suitable | Green | n/a | Hertfordshire and West Essex ICB |
Evorel conti | Hormone replacement therapy (HRT) Patches are 2nd choice when tablets not suitable | Green | n/a | Hertfordshire and West Essex ICB |
Exemestane | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Fampridine | Multiple sclerosis (NHSE) | Double Red | Decision document | Hertfordshire and West Essex ICB |
Faricimab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Faricimab | Wet Age-related Macular Degeneration, Diabetic macular oedema | Red | Decision document | Hertfordshire and West Essex ICB |
Febuxostat | Gout 2nd line | Green | n/a | Hertfordshire and West Essex ICB |
Femoston | Hormone replacement therapy (HRT) | Green | n/a | Hertfordshire and West Essex ICB |
Femoston conti | Hormone replacement therapy (HRT) | Green | n/a | Hertfordshire and West Essex ICB |
Fentanyl immediate release (IR) | Pain (except for palliative care) | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Fentanyl Immediate-Release Patient Information Leaflet | Pain (except for palliative care) | n/a | Patient information | Hertfordshire and West Essex ICB |
Ferric maltol | Iron deficiency | Double Red | n/a | Hertfordshire and West Essex ICB |
Filgotinib | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Filgotinib | Rheumatoid arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Filgotinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Filgrastim | Neutropenia (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Finerenone | Chronic kidney disease | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Fingolimod | Highly active relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Fluocinolone intravitreal implant | Diabetic macular oedema | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Fluocinolone intravitreal implant | Uveitis - non-infectious | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Fluorouracil 0.5% / Salicylic acid 10% cutaneous solution | Actinic keratosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Fluticasone furoate 27.5micrograms/dose nasal spray (Avamys®) | Allergic rhinitis 3rd line | Green | Decision document | Hertfordshire and West Essex ICB |
Fluticasone propionate 50micrograms/dose nasal spray (prescribed as Nasofan® only) | Allergic rhinitis 2nd line | Green | Decision document | Hertfordshire and West Essex ICB |
Fondaparinux | Thrombosis | Red | n/a | Hertfordshire and West Essex ICB |
Fostamatinib | Chronic immune thrombocytopenia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
FreeStyle Libre | Diabetes | Amber initiation | Patient information | Hertfordshire and West Essex ICB |
Fremanezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Fremanezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Fulvestrant | Locally advanced or metastatic breast cancer | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Gabapentin | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Galantamine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
Galcanezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Galcanezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB, East and North Hertfordshire, South and West Hertfordshire, West Essex |
Gefapixant | Refractory or unexplained chronic cough | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Gemfibrozil | Hypercholesterolaemia | Double Red | n/a | Hertfordshire and West Essex ICB |
Genital herpes | Genital herpes | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Gingivitis | Gingivitis - simple - mucosal ulceration and inflammation | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Gingivitis | Gingivitis - acute necrotising ulcerative | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Glatiramer | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Glucosamine and chondroitin | Osteoarthritis | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Glucosamine and Chondroitin Patient Information Leaflet | Osteoarthritis | n/a | Patient information | Hertfordshire and West Essex ICB |
Gluten Free food - Implementation Support | Coeliac disease | n/a | Prescribing guideline | West Essex |
Gluten Free food - Patient information | Coeliac disease | n/a | Patient information | South and West Hertfordshire |
Gluten free food - Prescribing guideline | Coeliac disease | n/a | Prescribing guideline | East and North Hertfordshire |
Gluten Free food - Prescribing guideline | Coeliac disease | n/a | Prescribing guideline | South and West Hertfordshire |
Gluten Free food - Prescribing guideline | Coeliac disease | n/a | Prescribing guideline | West Essex |
Gluten free food - Prescribing guideline exceptions | Coeliac disease | n/a | Prescribing guideline | East and North Hertfordshire |
Glyceryl trinitrate ointment 2nd line | Anal fissures | Green | n/a | Hertfordshire and West Essex ICB |
Glycopyrronium bromide | Hyperhidrosis | Double Red | Decision document | Hertfordshire and West Essex ICB |
Glycopyrronium bromide oral | Hypersalivation - adults | Double Red | n/a | Hertfordshire and West Essex ICB |
Glycopyrronium switch patient letter | Hypersalivation | Double Red | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Golimumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Golimumab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Golimumab | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Golimumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Gonorrhoea | Gonorrhoea | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Good practice guidance - Anticoagulation | Care homes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Good practice guidance - Controlled drugs | Care homes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Good practice guidance - Covert administration | Care homes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Good practice guidance - Emollients | Care homes | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Good practice guidance - Fridge temperature record | Care homes | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Good practice guidance - High Risk Drugs | Care homes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Good practice guidance - Homely remedy and self care | Care homes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Good practice guidance - Medicines reconciliation and transfer of care | Care homes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Good practice guidance - Omitted and delayed medicines | Care homes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Good practice guidance - Self-Administration of Medicines | Care homes | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Goserelin | Prostate cancer - 2nd line | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Grazoprevir | Hepatitis C (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Guanfacine | Atttention deficit hyperactivity disorder (ADHD) - in children | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Guanfacine | Atttention deficit hyperactivity disorder (ADHD) - in children | Amber protocol | Shared care protocol | West Essex |
Guidance for Self-monitoring of Blood Glucose (SMBG) for patients with Diabetes Mellitus | Diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Guselkumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Guselkumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Hay fever | Hay fever | n/a | Patient information | Hertfordshire and West Essex ICB |
Helicobacter pylori | Helicobacter pylori | Green | Decision document | Hertfordshire and West Essex ICB |
Herbal treatments and other natural products | All indication | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Herbal Treatments Patient Information Leaflet | All indications | n/a | Patient information | Hertfordshire and West Essex ICB |
Herpes zoster / shingles | Herpes zoster / shingles | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Homeopathy | All indications | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Homeopathy Patient Information Leaflet | All indications | n/a | Patient information | Hertfordshire and West Essex ICB |
How to guide: Searching HWE prescribing guidance website | n/a | n/a | Hertfordshire and West Essex ICB | |
Human and animal bites | Human and animal bites | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
HWEICS Shared Care Protocol for Liothyronine in a selected cohort of adults with hypothyrodisim | Hypothyroidism | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Hyaluronan, intra-articular injection | Osteoarthritis | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Hydrocortisone (Alkindi) | Adrenal insufficiency | Double Red | n/a | Hertfordshire and West Essex ICB |
Hydrocortisone (Plenadren) | Adrenal insufficiency | Double Red | n/a | Hertfordshire and West Essex ICB |
Hydroxycarbamide | Sickle Cell Disease | Red | n/a | Hertfordshire and West Essex ICB |
Hydroxycarbamide | Myeloproliferative neoplasms | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Hydroxychloroquine | Rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Hyoscine butylbromide | Irritable bowel syndrome (IBS) 1st line | Green | n/a | Hertfordshire and West Essex ICB |
Hyperhidrosis | Hyperhidrosis - self help | n/a | Patient information | Hertfordshire and West Essex ICB |
Hypertension guidelines in adults | Hypertension | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
iAluRil | Chronic inflammation or infection of the bladder | Double Red | Decision document | Hertfordshire and West Essex ICB |
Ibandronic acid - oral | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Ibandronic acid 50mg | Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Ibandronic acid IV | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Ibrutinib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Icosapent ethyl | Hypertriglyceridemia | Red | Decision document | Hertfordshire and West Essex ICB |
ICS wound care formulary | Wound care | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Imatinib | All indications (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Imiquimod 3.75% cream | Actinic keratosis | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Imiquimod 5% cream | Actinic keratosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Immediate Access to Emergency Drugs Scheme | Immediate Access to Emergency Drugs Scheme | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Impetigo | Impetigo | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Inclisiran | Primary hypercholesterolaemia and mixed dyslipidaemia | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Inclisiran | Primary hypercholesterolaemia and mixed dyslipidaemia | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Infections in Primary Care | Infections | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Infliximab IV | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Infliximab IV | Axial spondyloarthritis - ankylosing spondylitis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Infliximab IV | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Infliximab IV | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Infliximab IV | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Infliximab IV | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Infliximab IV | Rheumatoid arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Infliximab IV biosimilar | Diarrhoea or colitis associated with Immune Checkpoint Inhibitor therapy | Red | Decision document | Hertfordshire and West Essex ICB |
Influenza | Influenza | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Inhaled corticosteroids | Asthma COPD - ECF FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Inhaler - environmentally friendly | Asthma COPD | n/a | Patient information | Hertfordshire and West Essex ICB |
Inhaler reliever | Asthma | n/a | Patient information | Hertfordshire and West Essex ICB |
Inositol nicotinate | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Insect bites and stings | Insect bites and stings | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Inspection - CQC | Managing Medicines in a GP Practice | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Insulin degludec (Tresiba) | Diabetes | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Insulin Fiasp | Diabetes type 1 | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Insulin lispro (Lyumjev) | Diabetes type 1 | Double Red | n/a | Hertfordshire and West Essex ICB |
Intranasal corticosteroids | Allergic rhinitis | Green | Decision document | Hertfordshire and West Essex ICB |
Iron chelators | Blood transfusion related iron overload in patients with myelodysplastic syndrome | Double Red | Decision document | Hertfordshire and West Essex ICB |
Iron dextran | Iron deficiency | Red | n/a | Hertfordshire and West Essex ICB |
Isavuconazole | Antifungal (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Isotretinoin | Acne | Red | n/a | Hertfordshire and West Essex ICB |
Ispaghula husk (Fybogel) | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Ivabradine | stable angina and chronic heart failure | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Ivacaftor | Cystic fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Ivermectin 10mg/ml cream | Papulopustular rosacea | Green | Decision document | Hertfordshire and West Essex ICB |
IVF drugs | Infertility | Red | n/a | Hertfordshire and West Essex ICB |
Ixekizumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
ixekizumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
ixekizumab | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Joint Activities with the Pharmaceutical Industry | Pharmaceutical Industry | n/a | Position statement | Hertfordshire and West Essex ICB |
Kelhale inhaler | Asthma | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Ketone test strip | Diabetic ketoacidosis (DKA) sick day | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Lacosamide | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Lactulose | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Lamivudine | Hepatitis B (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Lamotrigine | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Lanthanum | Hyperphosphataemia in adult patients with chronic kidney disease | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Laxido | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Leflunomide | Rheumatoid Arthritis, Psoriatic Arthritis | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Leg ulcer infection | Leg ulcer infection | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Lenalidomide | Multiple myeloma follicular lymphoma (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Lenograstim | Neutropenia (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Letermovir | Cytomegalovirus (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Letrozole | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Leuprorelin | Prostate cancer - 2nd line | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Levetiracetam | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Lidocaine plaster patient information Leaflet | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
Lidocaine Plasters | All except post herpetic neuralgia and non post herpetic neuralgia localised neuropathy | Double Red | n/a | Hertfordshire and West Essex ICB |
Lidocaine plasters deprescribing guide | Neuropathic pain | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Linezolid | Antibacterial | Red | n/a | Hertfordshire and West Essex ICB |
Lipid management | patient decision aid statin therapy | n/a | Patient information | Hertfordshire and West Essex ICB |
Lipid management pathway | Statin intolerance | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Lipid management pathway | Primary & secondary prevention | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Liraglutide | Obesity in people aged 12 to 17 years | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Liraglutide | Overweight and obesity management | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Lisdexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
Lisdexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Lithium | Mania, hypomania, bipolar disorder, depression and aggressive or self-harming behaviour | Amber protocol | Shared care protocol | West Essex |
Lithium | Mania, hypomania, bipolar disorder, depression and aggressive or self-harming behaviour | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Lithium Primary Care action plan | Mania, hypomania, bipolar disorder, depression and aggressive or self-harming behaviour | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Lomitapide | Homozygous familial hypercholesterolaemia (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Long term insomnia management | Long-term insomnia | n/a | Patient information | Hertfordshire and West Essex ICB |
Loperamide | Diarrhoea | Green | n/a | Hertfordshire and West Essex ICB |
Low molecular weight heparin (LMWH) | Anticoagulation | Red | Decision document | Hertfordshire and West Essex ICB |
Loxapine | Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Lurasidone | Schizophrenia | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Lusutrombopag | Thrombocytopenia in chronic liver disease | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Lutein and Antioxidants | Eye Supplements for AMD | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Lutein and Antioxidants Patient Information Leaflet | Eye Supplements for AMD | n/a | Patient information | Hertfordshire and West Essex ICB |
Macitentan | Pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Macrogol | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Managing malnutrition - Additional guidance | Nutrition support - Malnutrition | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Mannitol dry powder for inhalation | Cystic fibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Mastitis | Mastitis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Mebeverine - immediate release (IR) | Irritable bowel syndrome (IBS) 1st line | Green | n/a | Hertfordshire and West Essex ICB |
Mebeverine - modified release (MR) | Irritable bowel syndrome (IBS) | Double Red | n/a | Hertfordshire and West Essex ICB |
Mecasermin | Growth failure (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Medication Overuse Headache | n/a | Decision document | South and West Hertfordshire | |
Medication Shortages | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB | |
Melatonin | Insomnia - Neurodevelopmental Disorders in patients under the age of 18 years | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Melatonin | Insomnia - Learning disability in adults and paediatrics | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Melatonin | Insomnia - product options in neurodevelopmental disorders in patients aged 2 to under 18 years | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Melatonin | Insomnia - product options in adult and paediatric patients with learning disabilities | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Melatonin | Insomnia adults excluding learning disabilities | Double Red | n/a | Hertfordshire and West Essex ICB |
Melatonin (Slenyto) | Insomnia | Double Red | Decision document | Hertfordshire and West Essex ICB |
Melphalan | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Memantine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
Meningitis | Meningitis - prevention of secondary case | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Meningococcal disease | Meningococcal disease - suspected | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Mepacrine (unlicensed medicine) | Subacute cutaneous and Discoid lupus erythematosus | Red | n/a | Hertfordshire and West Essex ICB |
Mercaptamine | Corneal cystine deposits (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
Mesalazine - Octasa preferred 1st choice | Inflammatory bowel disease | Green | n/a | Hertfordshire and West Essex ICB |
Mesalazine -Mezavant | Inflammatory bowel disease | Double Red | n/a | Hertfordshire and West Essex ICB |
Mesna | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Metformin | Diabetes type 2 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Methotrexate | Autoimmune disease | Amber protocol | Shared care protocol | West Essex |
Methotrexate | Autoimmune disease | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Methotrexate 10mg | Autoimmune disease | Double Red | n/a | Hertfordshire and West Essex ICB |
Methotrexate 2.5mg | Autoimmune disease | Amber protocol | Prescribing guideline | Hertfordshire and West Essex ICB |
Methoxsalen | Cancer, psoriasis | Red | n/a | Hertfordshire and West Essex ICB |
Methylnaltrexone bromide | Opioid induced bowel dysfunction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Methylnaltrexone bromide | Constipation - opioid induced | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Methylphenidate | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
Methylphenidate | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Methylphenidate | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Metolazone | Oedema | n/a | Patient information | Hertfordshire and West Essex ICB |
Metolazone | Oedema | Red | Decision document | Hertfordshire and West Essex ICB |
Mexiletine | Myotonia in non-dystrophic myotonic disorders (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Mexiletine | Life threatening ventricular arrhythmias (unlicensed - acute provider only) | Red | n/a | Hertfordshire and West Essex ICB |
Midazolam (Buccolam) | Epilepsy (prescribe by brand) | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Midazolam (Epistatus) | Epilepsy (prescribe by brand) | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Migraine | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Migraine | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Minocycline | Acne | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Minocycline Patient information leaflet | Acne | n/a | Patient information | Hertfordshire and West Essex ICB |
Mirena levonorgestrel-releasing intrauterine system (IUS) | Contraception | Green | Decision document | Hertfordshire and West Essex ICB |
Mirikizumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Mitomycin | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Mitotane | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Modafinil | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Mometasone 50micrograms/dose nasal spray | Allergic rhinitis 1st line | Green | Decision document | Hertfordshire and West Essex ICB |
Multi-compartment compliance aid and 7-day prescription guidance | Multi-compartment compliance aid | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Multi-compartment Compliance Aids | Reasonable adjustment | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Multi-compartment Compliance Aids | Assessment tool | n/a | n/a | Hertfordshire and West Essex ICB |
Multi-compartment Compliance Aids | Patient information | n/a | Patient information | Hertfordshire and West Essex ICB |
Mycophenolate mofetil | Multisystem autoimmune disease | Amber protocol | Shared care protocol | West Essex |
Mycophenolate mofetil | Multisystem autoimmune disease | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
Naftidrofuryl Oxalate | Intermittent claudication in people with peripheral arterial disease | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Naldemedine | Constipation - opioid induced | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Nalmefene | Reduction of alcohol consumption in adult patients who have a high drinking risk level without physical withdrawal risk | Amber initiation | Decision document | West Essex |
Nalmefene | Reduction of alcohol consumption in adult patients who have a high drinking risk level without physical withdrawal risk | Red | Decision document | East and North Hertfordshire, South and West Hertfordshire |
Naloxegol | Constipation - opioid induced | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Naltrexone–bupropion | Overweight and obesity | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Natalizumab | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Needles Patient Information Leaflet | Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB |
Neuropathic pain | Neuropathic pain | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Nevirapine | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
NICE NG28 Visual summary on choosing medicines for type 2 diabetes in adults | Type 2 diabetes | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Nicotinic acid | Prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Nintedanib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Nirmatrelvir plus ritonavir | Covid-19 (CMDU only) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Nitazoxanide | Viral hepatitis (B&C) and respiratory syncytial virus (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Nitrazepam | Insomnia | Double Red | n/a | Hertfordshire and West Essex ICB |
Obeticholic acid | Primary biliary cholangitis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ocriplasmin | Vitreomacular traction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Omalizumab | Urticaria - severe chronic | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Omega 3 fatty acid | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Omega 3 fatty acid | Hypertriglyceridaemia - severe | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Omega-3 Fatty Acids Patient Information Leaflet | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | n/a | Patient information | Hertfordshire and West Essex ICB |
Opicapone | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Opioid | Pain - persistent self care | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Opioid | Pain - plan agreement | n/a | Patient information | Hertfordshire and West Essex ICB |
Opioid | Pain - review letter | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Opioid Aware Campaign | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB | |
Opioid Deprescribing | Pain - long-term prescribing for non-cancer, chronic pain in adults | n/a | Position statement | Hertfordshire and West Essex ICB |
Opioid fact sheet | Pain | Green | Patient information | Hertfordshire and West Essex ICB |
Opioid Induced Constipation | Opioid Induced Constipation | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Opioid reduction | Opioid reduction tool | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Oral nutritional supplement (ONS) review in GP practice - Audit Tool | Nutrition support - Malnutrition | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Oral nutritional supplement (ONS) review in GP Practice - Supporting Guidance | Nutrition support - Malnutrition | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Orphenadrine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Osteoporosis | Osteoporosis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Otitis externa | Otitis externa - acute | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Otitis media | Otitis media - acute | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Over The Counter Medicines | Addendum to NHSE | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Over The Counter Medicines (OTC) | NHSE guidance | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Over The Counter Medicines (OTC) | When to prescribe | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Overprescribing and reducing harm from medicines Q&A | n/a | Prescribing support document | Hertfordshire and West Essex ICB | |
Oxcarbazepine | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Oxycodone and naloxone | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Oxycodone and Naloxone combination products Patient Information Leaflet | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
Oxygen | Home oxygen | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Oxygen | Cluster headache | n/a | Decision document | Hertfordshire and West Essex ICB |
Ozanimod | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Paediatric audit tool - CMPA | Paediatric Nutrition – CMPA | n/a | Prescribing support document | West Essex |
Paediatric audit tool - CMPA | Paediatric Nutrition – CMPA | n/a | Prescribing support document | South and West Hertfordshire |
Paediatric audit tool - CMPA | Paediatric Nutrition – CMPA | n/a | Prescribing support document | East and North Hertfordshire |
Paediatric cow's milk protein allergy (CMPA) - A guidance document | Paediatric Nutrition – CMPA | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Paediatric cow's milk protein allergy (CMPA) - A summary of HCP guidance & resources | Paediatric Nutrition – CMPA | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Paediatric cow's milk protein allergy (CMPA) - Advice for breastfeeding mums following a cow's milk free diet | Paediatric Nutrition – CMPA | n/a | Patient information | Hertfordshire and West Essex ICB |
Paediatric cow's milk protein allergy (CMPA) - Formula flow chart | Paediatric Nutrition – CMPA | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Paediatric cow's milk protein allergy (CMPA) - GP FAQs | Paediatric Nutrition – CMPA | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Paediatric cow's milk protein allergy (CMPA) - Managing supplies & when to stop the formula guidance | Paediatric Nutrition – CMPA | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Paediatric cow's milk protein allergy (CMPA) - Patient FAQs | Paediatric Nutrition – CMPA | n/a | Patient information | Hertfordshire and West Essex ICB |
Paediatric dietitian pathway – CMPA age 1 year & over | Paediatric Nutrition – CMPA | n/a | Prescribing pathway | South and West Hertfordshire |
Paediatric dietitian pathway – CMPA age under 1 year | Paediatric Nutrition – CMPA | n/a | Prescribing pathway | South and West Hertfordshire |
Paediatric faltering growth – Help my child is not eating | Paediatric Nutrition – Faltering Growth | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Paediatric faltering growth guidance | Paediatric Nutrition – Faltering Growth | n/a | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Paediatric formulas table - CMPA | Paediatric Nutrition – CMPA | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Paediatric gastro oesophageal reflux guidance | Paediatric Nutrition –GORD | Red | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Paediatric preterm infants guidance | Paediatric Nutrition –Preterm | n/a | Decision document | East and North Hertfordshire, South and West Hertfordshire |
Paediatric product recall - Alimentum & Elecare notification | Paediatric Nutrition – CMPA | n/a | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Paediatric secondary lactose intolerance guidance | Paediatric Nutrition – Lactose Intolerance | Red | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Paediatric specialist formula guidance | Paediatric Nutrition – Infant Formulas | n/a | Prescribing guideline | West Essex |
Palbociclib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Palforzia | Peanut allergy (Specialist allergy centre) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Palliative care formulary | Palliative care | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Panton-Valentine leukocidin (PVL) | Panton-Valentine leukocidin (PVL) | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Paracetamol and tramadol | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Paracetamol and Tramadol combination products Patient Information Leaflet | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
Paricalcitol | Hyperparathyroidism (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Patiromer | Hyperkalaemia of CKD | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
Pegfilgrastim | Neutropenia (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Peginterferon | All indication | Red | Decision document | Hertfordshire and West Essex ICB |
Pegvisomant | Acromegaly (NHSE tertiary centre only) | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Pelvic inflammatory disease (PID) | Pelvic inflammatory disease (PID) | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Pentosan polysulfate sodium | Bladder pain syndrome | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Pentoxifylline | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Peppermint oil | Irritable bowel syndrome (IBS) 1st line | Green | n/a | Hertfordshire and West Essex ICB |
Pericoronitis | Pericoronitis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Perindopril arginine | Heart failure, hypertension and prophylaxis of CV events | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Perindopril Arginine Patient information leaflet | Heart failure, hypertension and prophylaxis of CV events | n/a | Patient information | Hertfordshire and West Essex ICB |
Pharmacy First | Pharmacy First | n/a | n/a | Hertfordshire and West Essex ICB |
Pharmacy First referral decision aid | n/a | Decision document | Hertfordshire and West Essex ICB | |
Phenobarbital | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Phenytoin | Epilepsy | Green | n/a | Hertfordshire and West Essex ICB |
Phosphate enema (Cleen) | Constipation | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Pigmanorm | Melasma | Double Red | Decision document | Hertfordshire and West Essex ICB |
Pirfenidone | Idiopathic pulmonary fibrosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Pitolisant | Excessive daytime sleepiness caused by obstructive sleep apnoea | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Pneumonia | Pneumonia - community acquired | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Pneumonia | Pneumonia - hospital acquired | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Posaconazole | Fungal infections (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Potassium binders | Hyperkalaemia of CKD | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
Practice support - Memorandum of understanding between GP practices and medicines optimisation team | n/a | n/a | Hertfordshire and West Essex ICB | |
Pramipexole | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Prasugrel | Percutaneous coronary intervention (PCI) for treating acute coronary syndromes (ACS) | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Prednisolone | All indications - soluble tablet | n/a | Patient information | Hertfordshire and West Essex ICB |
Prednisolone enteric coated | All indications | Double Red | n/a | Hertfordshire and West Essex ICB |
Prescribing nutritional products/vitamin supplements - Position statement | Nutrition support - Malnutrition & Vitamin insufficiency | n/a | Position statement | Hertfordshire and West Essex ICB |
Prescription | Private consultation | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Prescription - NHSBSA | Organisation and prescriber changes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Prescription - repeat | Clerks hints and tips | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Prescription - repeat | Prescriber guide with tips | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Prescription duration | Decision aid | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Prescription duration 7 days | Process and communication for identification | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Prescription duration guidance | Prescription duration guidance | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Primidone | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Probiotics | Treatment or prevention of diarrhoea of any cause. | Double Red | Decision document | Hertfordshire and West Essex ICB |
Probiotics | Irritable bowel syndrome (IBS) | Double Red | n/a | Hertfordshire and West Essex ICB |
Procyclidine | Parkinson's disease | Green | n/a | Hertfordshire and West Essex ICB |
Promethazine | All indications | n/a | Position statement | Hertfordshire and West Essex ICB |
Prostatitis | Prostatitis - acute | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Proton pump inhibitors - paediatric | Gastro-protection | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Psoriasis | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Psoriasis | Psoriasis - severe localised | Red | Decision document | Hertfordshire and West Essex ICB |
Psoriatic Arthritis | Psoriatic Arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Pyelonephritis | Pyelonephritis - acute upper urinary tract | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Qtern | Diabetes type 2 | Double Red | Decision document | Hertfordshire and West Essex ICB |
Quetiapine | Schizophrenia and bipolar disorder | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Raloxifene | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Raloxifene | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Raltegravir | HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Ranibizumab | Diabetic retinopathy | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ranibizumab | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Ranibizumab | Vascular endothelial growth factor A inhibitor (anti-VEGF), Wet Age-related Macular Degeneration, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), Choroidal neovascularisation (CNV) associated with pathological myopia | Red | Decision document | Hertfordshire and West Essex ICB |
Rasagiline | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Rebates and National Procurement Pricing Agreements | n/a | n/a | Position statement | Hertfordshire and West Essex ICB |
Recording medications prescribed by other parties on GP clinical systems | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB | |
Reducing medicines waste in care homes - Care home staff | Care homes | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Reducing medicines waste in care homes - GP Practice Staff & Prescribers | Care homes | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Relugolix-estradiol-norethisterone acetate (Ryeqo) | Uterine fibroids | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Remdesivir | COVID‑19 | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Rheumatoid Arthritis - moderate | Rheumatoid Arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Rheumatoid Arthritis - severe | Rheumatoid Arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Rifaximin | Hepatic encephalopathy | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Riluzole | Amyotrophic Lateral Sclerosis (ALS) form of Motor Neurone Disease (MND) | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Rimegepant | Migraine - prevention | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Rimegepant | Migraine - treating | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
Risankizumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Risankizumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Risedronate | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Ritlecitinib | Alopecia areata - severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ritonavir | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Rituximab | Autoimmune haemolytic anaemia (AIHA) | Red | Decision document | Hertfordshire and West Essex ICB |
Rituximab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Rivaroxaban | Prevention of atherothrombotic events in patients after an acute coronary syndrome | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Rivaroxaban | Preventing atherothrombotic events in people with coronary or peripheral artery disease | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Rivastigmine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
Roflumilast | COPD | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Romiplostim | Chronic immune thrombocytopenia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Romosozumab | Osteoporosis | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ropinirole | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Rotigotine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Roxadustat | Anaemia with chronic kidney disease | Red | Decision document | Hertfordshire and West Essex ICB |
Rubefacients, benzydamine, mucopolysaccharide and cooling products (excluding topical NSAIDs and capsaicin) | Musculoskeletal pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Ruxolitinib | Polycythaemia vera (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ruxolitinib | Myelofibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Sacubitril valsartan | Heart failure | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Salamol - letter | Asthma COPD | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Salamol - poster | Asthma COPD | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Sarilumab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Sayana Press | Contraception | Green | Decision document | Hertfordshire and West Essex ICB |
Scabies | Scabies | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Scarlet fever (GAS) | Scarlet fever (GAS) | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Schools | Medicines in schools FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
ScriptSwitch | Process simple switches | n/a | Decision document | Hertfordshire and West Essex ICB |
Scriptswitch | Implementation for practices | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Secukinumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Secukinumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Secukinumab | Axial spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Selective serotonin reuptake inhibitors (SSRIs) | Irritable bowel syndrome (IBS) 3rd line unlicensed | Green | n/a | Hertfordshire and West Essex ICB |
Selective serotonin reuptake inhibitors (SSRIs) | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Selegiline | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Semaglutide | Overweight and obesity management - adults | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Semaglutide | Overweight and obesity management - young people aged 12 to 17 years | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Semaglutide | Diabetes type 2 | n/a | Patient information | Hertfordshire and West Essex ICB |
Senna | Constipation | Green | n/a | Hertfordshire and West Essex ICB |
Sevelamer | Hyperphosphateemia in adult patients with chronic kidney disease | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
SGLT2 inhibitors | Diabetes type 2 | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Shared care | Attention deficit hyperactivity disorder (ADHD) by Private Provider | Amber protocol | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Shared Care | Shared Care Principles | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Shared care | Initiation by a Private Provider | Amber protocol | Patient information | Hertfordshire and West Essex ICB |
Sildenafil (20mg tablets) | Pulmonary arterial hypertension (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
Silk Garments | Eczema dermatitis | n/a | Patient information | Hertfordshire and West Essex ICB |
Silk garments | Eczema dermatitis | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Silver dressings | Wound Care | n/a | Position statement | Hertfordshire and West Essex ICB |
Sinusitis | Sinusitis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Siponimod | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Sirolimus oral | Transplant rejection (prescribe by brand) NHSE for existing patients | Amber protocol | n/a | Hertfordshire and West Essex ICB |
Sitagliptin | Diabetes type 2 | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Sitagliptin | Diabetes type 2 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Sodium clodronate | Bone pain, hypercalcaemia of malignancy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Sodium cromoglicate | Food allergy | Double Red | Decision document | Hertfordshire and West Essex ICB |
Sodium oxybate | Narcolepsy with cataplexy (tertiary centre only) | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Sodium valproate | All indications | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Sodium zirconium | Hyperkalaemia of CKD | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
Solriamfetol | Excessive daytime sleepiness caused by narcolepsy (tertiary centre only) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Solriamfetol apnoea | Excessive daytime sleepiness caused by obstructive sleep apnoea | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Somatrogon (Ngenla) | Growth disturbance caused by growth hormone deficiency in children | Red | Decision document | Hertfordshire and West Essex ICB |
Sore throat | Sore throat - acute | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Sotrovimab | Covid-19 (CMDU only) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Spacer | Asthma COPD | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Specialist / Non-approved / Non-Formulary Medicines – Information for Patients | Patient information | n/a | Patient information | Hertfordshire and West Essex ICB |
Specials alternative guidance | Specials alternative guidance | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Statin patient decision aid - NICE | Hypercholesterolaemia | n/a | Patient information | Hertfordshire and West Essex ICB |
Steroid card | FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
STI screening | STI screening | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Stoma - accessories not for prescribing | Stoma | Double Red | Position statement | Hertfordshire and West Essex ICB |
Stoma - accessories not for prescribing | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - adhesive remover spray | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - adhesive remover spray wipes | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - adhesive remover wipes to spray | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - adhesive remover wipes to wipes | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - adhesive spray lotion | Stoma | Double Red | Position statement | Hertfordshire and West Essex ICB |
Stoma - adhesive spray lotion | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - Appliance Ordering Information for Patients | Stoma - DAC | n/a | Patient information | Hertfordshire and West Essex ICB |
Stoma - barrier cream | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - barrier cream | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - barrier ring seal washer | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - barrier ring seal washer | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - collars | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - collars | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - colostomy ileostomy urostomy bag quantities | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - colostomy ileostomy urostomy bag quantities | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - community ostomy service poster | Stoma - DAC | n/a | Prescribing support document | West Essex |
Stoma - discharge solidifying agent | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - discharge solidifying agent | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - elastic belts | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - elastic belts | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - flange extender retention strip | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - flange extender retention strip | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - gauze swab | Stoma | Double Red | Position statement | Hertfordshire and West Essex ICB |
Stoma - gauze swab | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - ICB Prescribing Guidelines for Stoma Appliances | n/a | Position statement | Hertfordshire and West Essex ICB | |
Stoma - ilex & Orahesive | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - pastes and fillers | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - Pastes and Fillers | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - peristomal skin protective foam applicators and wipes | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - peristomal skin protective foam applicators wipes | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - peristomal skin protective sprays | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - powder | Stoma | Green | Position statement | Hertfordshire and West Essex ICB |
Stoma - powder | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - Practical Guide to Stomas for Healthcare Professionals | Stoma | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Stoma - Practice appliance contractor letter | Stoma - DAC | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Stoma - product samples | Stoma | Double Red | Position statement | Hertfordshire and West Essex ICB |
Stoma - product samples | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma - Stoma related surgical procedures | Stoma | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Stoma - support garments | Stoma | n/a | Position statement | Hertfordshire and West Essex ICB |
Stoma - support garments | Stoma | n/a | Patient information | East and North Hertfordshire, South and West Hertfordshire |
Stoma and continence (appliance and accessories) prescription requests | Stoma - DAC | n/a | Position statement | Hertfordshire and West Essex ICB |
Stoma Appliance and Accessories Toolkit | Stoma | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Strontium | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Sucralfate | Gastrointestinal ulcers | Double Red | Decision document | Hertfordshire and West Essex ICB |
Sucroferric Oxyhydroxide | Hyperphosphataemia in adult patients with end stage renal failure requiring renal replacement therapy | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Sulfasalazine | Gastroenterology / Rheumatology | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Sunscreens | Protection against UV radiation (ACBS) | Green | Decision document | Hertfordshire and West Essex ICB |
Sunscreens | Protection against UV radiation (ACBS) | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Tacrolimus oral | Transplant rejection (prescribe by brand) NHSE for existing patients | Amber protocol | n/a | Hertfordshire and West Essex ICB |
Tadalafil | Penile rehabilitation | Red | n/a | Hertfordshire and West Essex ICB |
Tadalafil | Benign prostatic hyperplasia | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tamoxifen | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tapentadol IR | Pain - acute moderate to severe | Double Red | n/a | Hertfordshire and West Essex ICB |
Tenecteplase | Acute ischaemic stroke | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tenofovir | AIDS/ HIV Antiretroviral (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Teriflunomide | Relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Teriparatide | Osteoporosis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Testosterone | Menopause | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Testosterone | Menopause | n/a | Patient information | Hertfordshire and West Essex ICB |
Testosterone gel | Menopause | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Thalidomide | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Thickeners & thickened ONS guidance | Dysphagia | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Threadworm | Threadworm | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Ticagrelor | Preventing atherothrombotic events after myocardial infarction | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ticagrelor | Treatment of acute coronary syndromes | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tick bites (Lyme disease) | Tick bites (Lyme disease) | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Tildrakizumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Tioguanine | Leukaemia | Red | n/a | Hertfordshire and West Essex ICB |
Tirbanibulin | Actinic keratosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Tirzepatide | Diabetes type 2 | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tixagevimab plus cilgavimab | COVID‑19 | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tixagevimab plus cilgavimab | Covid-19 | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tobramycin (TOBI Podhaler) | Cystic fibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tocilizmuab | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Tocilizumab | Covid-19 | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tofacitinib | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Tofacitinib | Axial Spondyloarthritis - ankylosing spondylitis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Tofacitinib | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Tofacitinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Tolvaptan | Kidney disease - autosomal dominant polycystic | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tolvaptan | Hyponatraemia secondary to SIADH | Red | Decision document | Hertfordshire and West Essex ICB |
Topiramate | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Tralokinumab | Atopic dermatitis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Transanal irrigation | Bowel dysfunction | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Travel Vaccines Patient Information Leaflet | Hepatitis B, Rabies, BCG, Meningitis ACWY, Japanese Encephalitis, Yellow fever, Tick-borne encephalitis | n/a | Patient information | Hertfordshire and West Essex ICB |
Treatment for diabetic hypoglycaemia (hypos) - Position statement | Diabetes – Hypoglycaemia | n/a | Position statement | South and West Hertfordshire |
Tretinoin | Cancer (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
Trichomoniasis | Trichomoniasis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Trihexyphenidyl (Benzhexol) | Parkinson's disease | Green | n/a | Hertfordshire and West Essex ICB |
Trimipramine | Depression | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Trimipramine | Depression | n/a | Patient information | Hertfordshire and West Essex ICB |
Trimipramine - stopping and switching guidance | Depression | Double Red | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Triptorelin as Decapeptyl SR®– Gonadorelin analogue of choice within licensed indications | Prostate cancer - 1st line | Green | n/a | Hertfordshire and West Essex ICB |
Ulcerative colitis | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Ulipristal | Uterine fibroids | Double Red | Decision document | Hertfordshire and West Essex ICB |
Upadacitinib | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Upadacitinib | Atopic dermatitis - moderate severe | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Upadacitinib | Rheumatoid arthritis - severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Upadacitinib | Rheumatoid arthritis - moderate | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Upadacitinib | Axial Spondyloarthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Upadacitinib | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Upadacitnib | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Urinary incontinence | Adults | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Urinary tract infection | Urinary tract infection - lower | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Urinary tract infection | Urinary tract infection - recurrent | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Urinary tract infection | Urinary tract infection - catheter associated | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Urinary Tract Infections (UTI) | Recurrent - adult | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
User guide for Cancelling or Amending eRDs (EMIS and SI) | eRDs | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
User guide for eRD (EMIS and SI) | eRDs | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Ustekinumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Ustekinumab | Psoriasis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Ustekinumab | Psoriatic arthritis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Ustekinumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Utrogestan | Hormone Replacement Therapy (HRT) | Green | Decision document | Hertfordshire and West Essex ICB |
Vaginosis | Vaginosis - bacterial | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Varicella zoster / chickenpox | Varicella zoster / chickenpox | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Vedolizumab | Crohn's disease - moderate to severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Vedolizumab | Ulcerative colitis - moderate severe | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Venlafaxine | Depression, anxiety and panic disorders | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Venlafaxine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Vericiguat | Heart failure - chronic with reduced ejection fraction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Vernakalant | Atrial fibrillation | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Vigabatrin | Epilepsy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Vitamin B compound & compound strong - Position statement | Vitamin insufficiency | n/a | Prescribing guideline | East and North Hertfordshire, South and West Hertfordshire |
Vitamin B compound & compound strong - Position statement | Vitamin insufficiency | n/a | Prescribing guideline | West Essex |
Vitamin B12 - Position statement | Vitamin deficiency | n/a | Position statement | Hertfordshire and West Essex ICB |
Vitamin D - Adult and paediatric deficiency & insufficiency guidance | Vitamin deficiency | n/a | Prescribing guideline | West Essex |
Vitamin D - Adult deficiency & insufficiency guidance | Vitamin deficiency | n/a | Prescribing guideline | South and West Hertfordshire |
Vitamin D - Adult deficiency & insufficiency treatment flowchart | Vitamin deficiency | n/a | Prescribing guideline | South and West Hertfordshire |
Vitamin D - Adult treatment choices | Vitamin deficiency | n/a | Prescribing guideline | South and West Hertfordshire |
Vitamin D - Paediatric deficiency & insufficiency treatment flowchart | Vitamin deficiency | n/a | Prescribing guideline | South and West Hertfordshire |
Vitamin D - Paediatric treatment choices | Vitamin deficiency | n/a | Prescribing guideline | South and West Hertfordshire |
Vitamin D - Patient information 1 | Vitamin deficiency | n/a | Patient information | South and West Hertfordshire |
Vitamin D - Patient Information 1 | Vitamin deficiency | n/a | Patient information | East and North Hertfordshire |
Vitamin D - Patient information 2 | Vitamin deficiency | n/a | Patient information | South and West Hertfordshire |
Vitamin D - Patient information 2 | Vitamin deficiency | n/a | Patient information | East and North Hertfordshire |
Vitamin D & Care Homes - Position statement | Vitamin D insufficiency | n/a | Position statement | Hertfordshire and West Essex ICB |
Vitamin prescribing & bariatric surgery | Vitamin insufficiency | n/a | Prescribing guideline | West Essex |
Vitamin prescribing & private bariatric surgery | Vitamin insufficiency | n/a | Prescribing guideline | South and West Hertfordshire |
Vitamin prescribing & private bariatric surgery - Patient information | Vitamin insufficiency | n/a | Patient information | South and West Hertfordshire |
Voriconazole | Chronic pulmonary aspergillosis and fungal infections (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Vortioxetine | Major depressive episodes | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Wet AMD | Wet AMD | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Zolendronic acid | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |